<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01364558</url>
  </required_header>
  <id_info>
    <org_study_id>DIAZ.001.01</org_study_id>
    <nct_id>NCT01364558</nct_id>
  </id_info>
  <brief_title>A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers</brief_title>
  <official_title>A Three-Period, Three-Treatment, Six-Sequence Randomized Crossover Study of the Bioavailability and Pharmacokinetics of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers&quot;,</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Neurelis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to assess the bioavailability and
      pharmacokinetics of two formulations of diazepam after intranasal (nasal spray) and
      injectable diazepam after intravenous (I.V.) administration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diazepam is a medication that is used for the treatment of seizures. It was approved by the
      Food and Drug Administration (FDA) for use in the United States and is currently sold as
      Valium® tablets, Diazepam Injection and Diastat® rectal gel.

      This study will evaluate two intranasal (nasal spray) formulations of diazepam which will be
      supplied by Neurelis, Inc. The purpose of this clinical research study is to assess the
      bioavailability and pharmacokinetics of two formulations of diazepam after intranasal (nasal
      spray) and injectable diazepam after intravenous (I.V.) administration. &quot;Bioavailability&quot; is
      a measure of how much drug is absorbed and present in the blood. &quot;Pharmacokinetics&quot; means to
      study the way a drug enters and leaves the blood and tissues over time
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the Absolute Bioavailability of Two Intranasal Diazepam Formulations.</measure>
    <time_frame>2 days</time_frame>
    <description>To calculate bioavailability we used the following formula:
Area Under the Curve (Intranasal Spray)*100/Area Under the Curve (Intravenous Injection)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Diazepam Nasal Spray Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diazepam Nasal Suspension - 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diazepam Nasal Spray Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diazepam Nasal Spray Solution - 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diazepam injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diazepam injection IV - 5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam</intervention_name>
    <description>Diazepam will be administered as a 5 mg dose given IV. The two nasal formulations will be given as a 10 mg dose.</description>
    <arm_group_label>Diazepam Nasal Spray Suspension</arm_group_label>
    <arm_group_label>Diazepam Nasal Spray Solution</arm_group_label>
    <other_name>Brand names include: Valium, Diastat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam</intervention_name>
    <description>IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.</description>
    <arm_group_label>Diazepam Nasal Spray Suspension</arm_group_label>
    <arm_group_label>Diazepam Nasal Spray Solution</arm_group_label>
    <arm_group_label>Diazepam injection</arm_group_label>
    <other_name>Valium Injectable, Diastat Rectal Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects between the ages of 18 and 45 years (inclusive).

          2. Written informed consent to participate in the study.

          3. Body mass index (BMI) between 19 and 30 kg/m², inclusive.

          4. Female subjects of childbearing potential, defined as not surgically sterile or at
             least two years (2) postmenopausal, must agree to use one of the following forms of
             contraception from three (3) months prior through 12 days following the last dose of
             study drug: hormonal (oral, transdermal, implant, or injection), barrier (condom,
             diaphragm with spermicide), IUD, or vasectomized partner (six months minimum).
             Subjects must have used the same method for at least three (3) months prior to
             starting the study.

          5. No clinically significant abnormal findings in the medical history, on the physical
             examination, electrocardiogram (ECG), or clinical laboratory results during Screening.

          6. Subjects must agree to return to the study site for all study visits, including the
             three (3) confinement periods, and must be willing to comply with all required study
             procedures.

        Exclusion Criteria:

          1. A history of clinically significant gastrointestinal, renal, hepatic, neurologic,
             hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or
             cardiovascular disease, severe seasonal or non seasonal allergies, nasal polyps or any
             nasal passage abnormality that could interfere with nasal spray administration, or any
             other condition which, in the opinion of the Principal Investigator, would jeopardize
             the safety of the subject or impact the validity of the study results.

          2. A history of allergic or adverse responses to diazepam or any comparable or similar
             product.

          3. Subjects who (for whatever reason) have been on an abnormal diet (such as one that
             severely restricts specific basic food groups [e.g., ketogenic diet], limits calories
             [e.g., fast], and/or requires the use of daily supplements as a substitute for the
             foods typically eaten at mealtimes), during the four (4) weeks preceding the study.

          4. Subjects who donated blood or plasma within 30 days of the first dose of study drug.

          5. Participation in a clinical trial within 30 days prior to the first dose of study
             drug. Participation in an observational (non interventional) study is not excluded as
             long as there are no scheduling conflicts with this study.

          6. Inadequate or difficult venous access that may jeopardize the quality or timing of the
             PK samples.

          7. Use of any over the counter (OTC) medication, including vitamins, within seven (7)
             days prior to the first dose of the study drug or during the study, unless approved by
             the Principal Investigator.

          8. Use of any prescription medication, including benzodiazepines, within 14 days prior to
             the first dose of study drug or during the study, with the exception of hormonal
             contraceptives for women of childbearing potential, unless approved by the Principal
             Investigator.

          9. Treatment with any known enzyme altering drugs such as barbiturates, phenothiazines,
             cimetidine, carbamazepine, etc., within 30 days prior to the first dose of study drug
             or during the study.

         10. Smoking or use of tobacco products within six (6) months prior to the first dose of
             study drug or during the study.

         11. Female subjects who are trying to conceive, are pregnant, or are lactating.

         12. Positive serum pregnancy test at Screening or urine pregnancy test prior to each
             administration of study drug for all women, regardless of childbearing potential.

         13. Positive blood screen for HIV, Hepatitis B surface antigen (HbSAg), or Hepatitis C, or
             a positive urine screen for alcohol, drugs of abuse, or cotinine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Cloyd, Pharm D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prism Clinical Research Unit</name>
      <address>
        <city>St.Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2011</study_first_posted>
  <results_first_submitted>July 20, 2012</results_first_submitted>
  <results_first_submitted_qc>May 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 20, 2014</results_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diazepam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All 24 subjects were given each formulation with a two week wash out period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Diazepam Nasal Spray Suspension</title>
          <description>Diazepam Nasal Spray Suspension</description>
        </group>
        <group group_id="P2">
          <title>Diazepam Nasal Spray Solution</title>
          <description>Diazepam Nasal Spray Solution</description>
        </group>
        <group group_id="P3">
          <title>Diazepam Injection</title>
          <description>Diazepam injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Dose One</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Dose Two</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Dose Three</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diazepam Nasal Spray Suspension/Spray/Injection</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.2" spread="7.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comparison of the Absolute Bioavailability of Two Intranasal Diazepam Formulations.</title>
        <description>To calculate bioavailability we used the following formula:
Area Under the Curve (Intranasal Spray)*100/Area Under the Curve (Intravenous Injection)</description>
        <time_frame>2 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diazepam Nasal Spray Suspension</title>
            <description>Diazepam Nasal Spray Suspension</description>
          </group>
          <group group_id="O2">
            <title>Diazepam Nasal Spray Solution</title>
            <description>Diazepam Nasal Spray Solution</description>
          </group>
          <group group_id="O3">
            <title>Diazepam Injection</title>
            <description>Diazepam injection</description>
          </group>
        </group_list>
        <measure>
          <title>Comparison of the Absolute Bioavailability of Two Intranasal Diazepam Formulations.</title>
          <description>To calculate bioavailability we used the following formula:
Area Under the Curve (Intranasal Spray)*100/Area Under the Curve (Intravenous Injection)</description>
          <units>Percentage of Bioavailability</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="64" upper_limit="75"/>
                    <measurement group_id="O2" value="96.82" lower_limit="90" upper_limit="105"/>
                    <measurement group_id="O3" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Diazepam Nasal Spray Suspension</title>
        </group>
        <group group_id="E2">
          <title>Diazepam Nasal Spray Solution</title>
        </group>
        <group group_id="E3">
          <title>Diazepam Injection</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respitory, thoracic, and mediastinal disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. James Cloyd, Director for Center for Orphan drug research</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-624-4609</phone>
      <email>cloyd001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

